Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007792.pdf
0001179110-20-007792.rtf
0001179110-20-007792.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007793.pdf
0001179110-20-007793.rtf
0001179110-20-007793.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007789.pdf
0001179110-20-007789.rtf
0001179110-20-007789.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007791.pdf
0001179110-20-007791.rtf
0001179110-20-007791.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007794.pdf
0001179110-20-007794.rtf
0001179110-20-007794.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007790.pdf
0001179110-20-007790.rtf
0001179110-20-007790.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007795.pdf
0001179110-20-007795.rtf
0001179110-20-007795.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007796.pdf
0001179110-20-007796.rtf
0001179110-20-007796.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-20-007819.pdf
0001558370-20-007819.rtf
0001558370-20-007819.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-007760.pdf
0001179110-20-007760.rtf
0001179110-20-007760.xls